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Abstract
Introduction: Establishing analytical performance requirements for in vitro diagnostic (IVD) assays is a challenging process. Manufacturers try 
to optimize analytical performance by choosing amongst many combinations of different product performance characteristics. Sigma metrics and 
method decision charts can be helpful aids in choosing appropriate analytical performance requirements. The objective of this research was to de-
monstrate the use of Sigma metrics and method decision charts to help establish analytical performance requirements and to optimize analytical 
performance at medical decision concentrations for an IVD assay.
Materials and methods: A range of possible Sigma metrics were determined using three sources for total allowable error (TEa) and hypothetical 
total PSA assay results. Method decision charts were created for each TEa source and used to identify the maximum precision and bias that the assay 
could have to maintain sigma level performance of at least 3. 
Results: To achieve a sigma performance level of at least 3 for a hypothetical total PSA assay, the maximum allowable coefficient of variation ran-
ged from 5.0% to 11.2% depending on the TEa source. To achieve a sigma performance level of at least 6, the maximum allowable coefficient of 
variation ranged from 2.5% to 5.6% depending on the TEa source.
Conclusions: Using Sigma metrics and method decision charts when establishing analytical performance requirements can help manufacturers 
choose product requirements that will optimize IVD assay product performance.
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Introduction
Sigma metrics can be used in many ways: to set 
quality control rules, to describe the performance 
of multiple assays using a single measurement 
procedure, to compare the performance of multi-
ple measurement procedures for a single type of 
assay, and to describe assay analytical perfor-
mance for external quality assessment partici-
pants (1-5). Sigma metrics can also be used in a 
product development setting (6). 
One of the most challenging tasks for an in vitro 
diagnostic (IVD) assay’s product development 
team is to agree upon the analytical performance 
requirements. To an outsider, the task may seem 
straightforward: identify the intended use and in-
tended users of the product, ask the prospective 
users for their needs for such an assay, and use the 
responses to develop the product’s requirements. 
Often, the needs are high-level: users want an as-
say that is easy to use, accurate, precise and relia-
ble, but the developer needs to know how accu-
rate and how precise. To answer these questions, 
one can start by considering how much the assay’s 
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reported result can vary from the true value with-
out impacting the treatment of a patient. In meas-
uring a sample’s concentration, there is inherent 
uncertainty comprised of a combination of sys-
tematic error (i.e. bias) and random error (i.e. im-
precision). This analytical variation is in addition to 
the uncertainty caused by pre-analytical and bio-
logical variation, all three sources of which contrib-
ute to overall test result variation (7). If the report-
ed analyte concentration is close enough to the 
true analyte concentration so that the treatment 
of the patient will be the same, the deviation from 
the true value can be acceptable. This allowable 
deviation is commonly referred to as the total er-
ror allowable (TEa) and can be expressed in abso-
lute or relative (percentage) units from the true 
value. A Sigma metrics considers the TEa, bias and 
precision to provide a single value for assessing 
the quality of a process based on a single concen-
tration level at a given point in time and is calcu-
lated as: sigma = (TEa - |bias|) / precision (8). Sigma 
metrics can be used as an aid to eliminate defects 
and reduce variability. In the context of a labora-
tory setting, defects are assay results that could 
cause a misclassification where the physician sug-
gests an incorrect course of action for a patient. 
Organizations using Sigma metrics often refer to 
processes as ranging from a 1-sigma to 6-sigma (or 
better) process. A 3-sigma assay is generally con-
sidered the minimum acceptable performance, 
whereas as a 6-sigma assay is considered world-
class (9). The sigma level of an assay can be used to 
determine the quality control (QC) routine needed 
for an assay, where higher sigma values require 
fewer levels of QC material or less frequent QC 
monitoring. Higher sigma levels mean fewer de-
fects and higher confidence in laboratory results.
The practice of using Sigma metrics to improve 
and design high quality products has been around 
for several decades (6). One problem IVD manufac-
turers face in using Sigma metrics, however, is to 
determine which TEa goal to use during product 
development since TEa values for many measur-
ands differ greatly, depending on the source. 
While there is a recommended hierarchy to con-
sider when choosing an appropriate TEa, there is 
no uniform consensus on which source is most ap-
propriate for a given measurand (10).
The objective of this research was to demonstrate 
the use of Sigma metrics and method decision 
charts to help establish analytical performance re-
quirements for an IVD assay.
Materials and methods
Total prostate-specific antigen (PSA) was chosen 
as an example for establishing analytical perfor-
mance requirements for multiple reasons. First, 
there are multiple sources of TEa for total PSA. Sec-
ond, total PSA has more than one intended use – it 
may be used for screening subjects for prostate 
cancer or for monitoring patients (11). Lastly, total 
PSA has generally accepted medical decision con-
centrations (11,12). 
Six TEa sources, noted in Figure 1, were consid-
ered. The European Federation of Clinical Chemis-
try and Laboratory Medicine (EFLM) published a 
recommended hierarchy for choosing an appro-
priate TEa whereby setting required performance 
specifications are based on three possible models: 
clinical outcomes, biological variability, and state-
of-the-art (10). None of the sources based their TEa 
specifications on clinical outcomes. Two of the 
sources (Czech Republic external quality assur-
ance program (SEKK) and guidelines of the Ger-
man medical association for the quality assurance 
of laboratory medical examinations (RiliBÄK)) are 
more reflective of specifications based on state-of-
the-art (model 3), whereas the remaining four 
sources are based on biological variability (model 
2) (13,14). It is interesting to note that while Ricos, 
Spanish minimum and Royal College of Patholo-
gists of Australasia (RCPA) claim to be based on bi-
ological variability, there is a four-fold difference in 
values between the highest and lowest specifica-
tions (15-17). It is not obvious why there is such a 
large difference but it may be due to the different 
studies used to determine biological variability. It 
should be noted, however, that for total PSA, the 
RCPA TEa is ± 0.4 µg/L up to 5.0 µg/L PSA, and ± 
8% > 5.0 µg/L PSA. Similarly, there is a difference of 
10% in the two total PSA TEa specifications based 
on state-of-the-art (25% RiliBÄK TEa vs 15% Czech 
SEKK TEa). These differences illustrate the difficulty 
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manufacturers and laboratories have in deciding 
which TEa source is most appropriate. Of these six 
sources, three were used in the assessment: Ricos-
desirable, RiliBÄK and Czech SEKK. These three 
sources were chosen because of their clearly dif-
ferent total PSA TEa values (33.6% for Ricos, 25% 
for RiliBÄK and 15% for Czech SEKK) and because 
they represented sources based on biological vari-
ability (Ricos) and state-of-the-art (Czech SEKK and 
RiliBÄK). Furthermore, the Spanish minimum (17%) 
and Ricos-optimal (16.8%) TEa values were similar 
to those of Czech SEKK (15%). 
A range of possible Sigma metrics were deter-
mined using Ricos-desirable, RiliBÄK and Czech 
SEKK sources for TEa to create a method decision 
chart using Microsoft Excel 2016 (18). These charts 
were used to identify the maximum precision and 
bias that the assay could have and still meet speci-
fied sigma levels.
Hypothetical values for total PSA precision and 
bias were given for three formulations (A, B and C) 
at three concentrations (4.0, 10.0 and 20.0 µg/L), 
and the Sigma metrics at each concentration was 
determined using the formula: sigma = (TEa - 
|bias|) / precision. The sigma values were plotted 
on a normalized method decision chart so the re-
sults could be compared, plotting the percent bias 
and percent coefficient of variation (CV) as a per-
centage of TEa (18). The two values on the x- and 
y- axes that were used to create the sigma lines are 
derived from the formula: sigma = (TEa - |bias|) / 
precision. Theoretically, if there is 0 imprecision, 
then the bias can be at the TEa limit. Similarly, if 
there is 0% bias, then the maximum allowable pre-
cision is equal to TEa / sigma. For example, with a 
TEa limit of 15% and 0% bias, then the imprecision 
would be 15% CV for a sigma value of 1, 7.5% CV 
for a sigma value of 2, and so on. 
Results
To achieve a sigma performance level of at least 6 
while assuming zero bias, the maximum allowable 
CV was 2.5% using Czech SEKK (Figure 2), 4.2% us-
ing RiliBÄK (Figure 3), and 5.6% using Ricos-desira-
ble (Figure 4) as TEa sources. The bias theoretically 
could be up to the same limit as the TEa specifica-
Figure 1. Sources for total allowable error (TEa) specifications 
used to establish analytical performance requirements for total 
prostate specific antigen (13-17)
Figure 2. Method decision chart for total prostate specific anti-
gen when using Czech SEKK total allowable error specification 
of 15% (13)
Figure 3. Method decision chart for total prostate specific an-
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tion while maintaining a given sigma perfor-
mance, but only under the unrealistic scenario that 
the assay has perfect precision (i.e. 0 %CV). To 
achieve a sigma performance level of at least 3 
while assuming zero bias, the maximum allowable 
CV was 5.0% using Czech SEKK (Figure 2), 8.3% us-
ing RiliBÄK (Figure 3), and 11.2% using Ricos-desir-
able (Figure 4) as TEa sources. 
During the research phase of product develop-
ment, assay development scientists show the 
product development team data from feasibility 
studies. The team will review the data and choose 
a final formulation with which to proceed for prod-
uct design verification and validation. Commonly 
used total PSA medical decision concentrations for 
prostate cancer screening range from 2.5 to 10.0 
µg/L but the medical decision range for monitor-
ing can span from the assay’s lower limit of quanti-
tation to 20.0 µg/L or more (11). To illustrate the 
types of choices a manufacturer might face when 
choosing an assay formulation, hypothetical preci-
sion and bias results were used for three formula-
tions of a total PSA assay (formulations A, B and C) 
for three samples at different concentrations: 4.0, 
10.0 and 20.0 µg/L. The samples at 4.0 and 10.0 
µg/L are within the medical decision range of total 
PSA, while the third sample is above the medical 
decision range though still within the measuring 
interval of the hypothetical assay. The results are 
shown in Table 1 and the Sigma metrics are plot-
ted on a normalized method decision charts in 
Figures 5, 6 and 7, with each chart showing the sig-
Sigma values based on specified total allowable error sources












4 µg/L 7 2 4.5 3.3 1.9
10 µg/L 5 5 5.7 4.0 2.0
20 µg/L 3 6 9.2 6.3 3.0
B
4 µg/L 3 2 10.5 7.7 4.3
10 µg/L 5 7 5.3 3.6 1.6
20 µg/L 7 6 3.9 2.7 1.3
C
4 µg/L 3 6 9.2 6.3 3.0
10 µg/L 5 8 5.1 3.4 1.4
20 µg/L 7 2 4.5 3.3 1.9
*Formulation refers to different physical properties of the assay, such as different concentrations of proteins, antibodies, detergents, 
salt, etc. Total PSA concentration depicts multiple total PSA values in the analytical measuring interval that are critical for patient 
management decisions. PSA – prostate specific antigen. CV(%) - coefficient of variation which would typically be derived from a 
20-day precision study. Bias(%) - relative bias. TEa - total allowable error. Ricos desirable TEa is 33.6%. RiliBÄK TEa is 25%. RiliBÄK - 
guidelines of the German medical association for the quality assurance of laboratory medical examinations. Czech SEKK TEa is 15%. 
SEKK - Czech Republic external quality assurance program.
Figure 4. Method decision chart for total prostate specific anti-
gen when using Ricos desirable total allowable error specifica-
tion of 33.6% (15)
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ma value for a different TEa source. Figures 5, 6 
and 7 were created using the data shown in Table 
1. The %CV and %bias values for each sample con-
centration for each three assay formulations (A, B, 
C) were divided by a TEa requirement and plotted 
on a normalized method decision chart, where the 
x-axis is the normalized %CV (CV as a percentage 
of %TEa) and the y-axis is the normalized %Bias 
(bias as a percentage of %TEa). The numerical la-
bels on each graph identify the hypothetical µg/L 
concentrations of total PSA samples.
Given the hypothetical data provided in the Table 
1 and the normalized method decision chart in 
Figures 5, 6 and 7, an assay development team 
would try to determine which of the three hypo-
thetical total PSA formulations could achieve the 
highest quality performance. None of the formula-
tions reflect 6 sigma quality across all samples us-
ing any of the TEa specifications; however, the 
sample at 20.0 µg/L using formulation A and the 
sample at 4.0 µg/L using formulations B and C had 
sigma values greater than 6 when using Ricos de-
sirable or RiliBÄK TEa specifications. Since the sam-
ple at 20.0 µg/L is not within the medical decision 
range but the sample at 4.0 µg/L is, the assay de-
velopment team would likely place greater value 
on having higher quality performance on the sam-
ple at 4.0 µg/L. 
From Figures 2 – 4 one can see that the maximum 
CV required to achieve the minimum acceptable 
sigma of 3 is 5.0%, 8.3% or 11.2% when assuming 
zero bias, depending on the TEa source. From Ta-
ble 1, laboratories using Czech SEKK TEa values 
could only achieve 3 sigma performance on one 
sample from each formulation, suggesting that 
this assay might not be marketable to those cus-
tomers. Laboratories using RiliBÄK TEa values 
could achieve 6 sigma performance for one sam-
ple and at least 3 sigma performance for two sam-
ples using formulations A and C, but did not per-
form as well using formulation B. This suggests 
that the team may want to rule out formulation B. 
The Sigma metrics using the Ricos desirable TEa 
demonstrate that the assay can achieve at least 4 
sigma performances on formulations A and C. 
Since the performance at medical decision con-
centrations of 4.0 µg/L and 10.0 µg/L is more criti-
Figure 5. Normalized method decision chart showing sigma 
values for three hypothetical formulations of a total prostate 
specific antigen (PSA) assay at three total PSA µg/L concentra-
tions for Czech SEKK total allowable error (TEa) of 15% (13)
Figure 6. Normalized method decision chart showing sigma 
values for three hypothetical formulations of a total prostate 
specific antigen (PSA) assay at three total PSA µg/L concentra-
tions for RiliBÄK total allowable error (TEa) of 25% (14)
Figure 7. Normalized method decision chart* showing sigma 
values for three hypothetical formulations of a total prostate 
specific antigen (PSA) assay at three total PSA µg/L concentra-
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cal than the performance at 20.0 µg/L and formu-
lation C has higher sigma performance at 4.0 µg/L, 
formulation C appears to be the best choice in 
maintaining the highest quality performance 
amongst the three options.
Discussion
With a 3-sigma assay being generally considered 
the minimum acceptable performance and a 
6-sigma assay performance considered world-
class, Sigma metrics and method decision charts 
can be used to help determine the optimal formu-
lation for a product as illustrated with the hypo-
thetical total PSA example (9). Additionally, the ex-
ample showed that Sigma metrics and method 
decision charts could be used to determine the 
upper limits of the bias and precision values that 
should be considered during the development of 
an IVD product. Furthermore, manufacturers can 
create different method decision charts for differ-
ent total error requirements. While a manufactur-
er’s assay may be developed with a target market 
in mind, and the manufacturer might assume 
most laboratories within the target market would 
use a specific TEa source, understanding how lab-
oratories that use a different TEa source can aid 
the manufacturer in advising the laboratory. This 
information can also assist the laboratory in know-
ing the kind of performance to expect.
Another point to consider when using Sigma met-
rics is that bias and precision influence the Sigma 
metrics differently, with precision having a greater 
impact. Petersen and Klee elaborate on this topic 
2014 in their paper (19). 
This exercise used total PSA as an example of how 
performance specifications for bias and precision 
could be set. It should be noted that there is not a 
certified reference material for total PSA and thus 
the bias aspect of the analyte could only be esti-
mated relative to a stated total PSA method or ma-
terial. While the bias for total PSA is not a bias in 
the sense that it is estimated against a universally 
recognized true value, this exercise was meant to 
demonstrate how Sigma metrics could be used 
during product development and the analyte is an 
example meant to illustrate the concept. 
There are several limitations with this approach, 
one of the most obvious being that there are many 
other factors besides precision, bias and sigma 
performance must be considered when making 
decisions during product development. The ex-
ample is intentionally over-simplified to highlight 
the key details in the decision-making process. 
During the actual product development process, 
many other factors including stability, manufac-
turability, cost, etc., must be considered when 
choosing amongst various product formulations. 
Another limitation is that not all laboratories use 
Sigma metrics or TEa specifications, so even if the 
manufacturer develops a product with sigma per-
formance in mind, the optimization may not trans-
late to the needs of those laboratories. Additional-
ly, any estimate of sigma performance is just a 
snapshot in time and can vary across different 
concentrations of the measurand. Despite such 
limitations, designing products with high quality 
performance in mind up front will still result in 
better quality in the long run. 
In conclusion, using Sigma metrics and method 
decision charts when establishing analytical per-
formance requirements can help manufacturers 
choose requirements that will optimize IVD assay 
product performance.
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